Amsterdam 2013 Programme Satellite Meetings Registration Exhibition Virtual Exhibition Hotels Visa Letter Invitation
Search Abstracts by author or title
(results will display both Free Papers & Poster)

The effect of microcoaxial cataract surgery on primary angle closure glaucoma

Poster Details

First Author: E.Özyol TURKEY

Co Author(s):    P. Özyol              

Abstract Details



Purpose:

To evaluate effect of microcoaxial cataract surgery on primary angle-closure glaucoma (PACG) and surgical complications.

Setting:

Department of Ophthalmology, Ünye State Hospital, Ordu, Turkey

Methods:

Fifteen eyes of 12 patients with PACG and scheduled for cataract surgery comprised the study group, 15 eyes of 13 patients scheduled for cataract surgery were included as control group in this prospective study. Microcoaxial cataract surgery was performed to all eyes. Anterior chamber depth, angle of anterior chamber, change in intraocular pressure (IOP), number of antiglaucomatous medications, and complications were recorded. Measurements were performed 3 days before, and first, second, third month control after surgery.

Results:

While preoperative mean anterior chamber depth in eyes with PACG was 2.21ḟ0.5 mm, it was measured as 3.5ḟ0.4 mm on third month control (p<0.001). The decrease in rate of eyes with grade 0-1 angles, and increase in rate of grade 2-3 angle at 3 months was statistically significant. While the mean corrected IOP was 17.9ḟ3.1 mm Hg with topical antiglaucomatous medications, it was 15.9ḟ3.8 mm Hg at 3 months. The mean number of antiglaucomatous medications was detected as 2.1ḟ0.4 preoperatively, and 1.1ḟ0.9 at 3 months. During surgery, in 1 eye zonular dialysis, in 1 eye paracentral endothelial damage occured. In control group, the change in anterior chamber depth was statistically significant (p< 0.01), whereas the change in anterior chamber angle, and IOP was not significant (p>0.05).

Conclusions:

The quality of life in patients with cataract surgery in eyes PACG can be increased by obtaining lower IOP, necessity of less number of antiglaucomatous medications, and better visual acuity.

Financial Disclosure:

NONE

Back to previous